Jump to main content
Jump to site search

Issue 1, 2016
Previous Article Next Article

Exploiting developments in nanotechnology for the preferential delivery of platinum-based anti-cancer agents to tumours: targeting some of the hallmarks of cancer

Author affiliations

Abstract

Platinum drugs as anti-cancer therapeutics are held in extremely high regard. Despite their success, there are drawbacks associated with their use; their dose-limiting toxicity, their limited activity against an array of common cancers and patient resistance to Pt-based therapeutic regimes. Current investigations in medicinal inorganic chemistry strive to offset these shortcomings through selective targeting of Pt drugs and/or the development of Pt drugs with new or multiple modes of action. A comprehensive overview showcasing how liposomes, nanocapsules, polymers, dendrimers, nanoparticles and nanotubes may be employed as vehicles to selectively deliver cytotoxic Pt payloads to tumour cells is provided.

Graphical abstract: Exploiting developments in nanotechnology for the preferential delivery of platinum-based anti-cancer agents to tumours: targeting some of the hallmarks of cancer

Back to tab navigation
Please wait while Download options loads

Publication details

The article was received on 03 Jul 2015, accepted on 02 Oct 2015 and first published on 16 Nov 2015


Article type: Critical Review
DOI: 10.1039/C5MT00181A
Citation: Metallomics, 2016,8, 43-60
  •   Request permissions

    Exploiting developments in nanotechnology for the preferential delivery of platinum-based anti-cancer agents to tumours: targeting some of the hallmarks of cancer

    J. P. Parker, Z. Ude and C. J. Marmion, Metallomics, 2016, 8, 43
    DOI: 10.1039/C5MT00181A

Search articles by author